This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Definitive treatment of prostate cancer is limited to radical surgery or radiation therapy for localized or regional disease. Gene transfer technology offers the potential for the development of new therapies for prostate cancer. This project will employ the unique apoptotic agent, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and a collagen-based matrix that enhances gene delivery system to augment immune activation. The long-term objective of the project is to develop an effective treatment for prostate cancer. Specifically, treatment involves the viral-mediated transfer of the gene for the cytotoxic protein TRAIL into the prostate, resulting in prostate tumor cell apoptotic death and activation of systemic antitumor immunity. These studies will help develop methods to maximize gene delivery and determine the toxicity and effectiveness of localized gene transfer therapy which could provide the basis for future studies leading to a new therapeutic approach for prostate cancer.
Showing the most recent 10 out of 381 publications
